Barnaby Pickering
Reporter, Medtech Insight
Graduating in 2020 with a Master’s degree in biomedical engineering from University College London, Barnaby is passionate about all things medtech. In his first role as a journalist, Barnaby will focus on R&D and commercial stories in medtech, and writing about emerging technologies such as digital health, artificial intelligence, machine learning, deep-brain implants, and nanoscale applications of medtech. Alongside this, Barnaby is looking forward to taking deeper dives into start-ups, device market analysis, and company financial data, to create informed, useful, and engaging content.
Barnaby lives in in rural Wiltshire, UK and is a keen reader, cyclist, and hobbyist jeweler.
Latest From Barnaby Pickering
Device Week, 19 November 2021 – J&J Break-Up, And Genomic Diagnostics
On this episode of Device Week, Medtech Insight’s Marion Webb explains the recent announcement that Johnson & Johnson will split into two separate businesses – one focusing on medical products, and the other focusing on consumer. Barnaby Pickering discusses recent results from the UK’s 100,000 Genome project, and how its analysis partner, Congenica, hopes to deliver personalized medicine through widescale genomic testing.
Angle Outlines Strategy As It Nears Major Regulatory Announcements
With approvals looming over the next few months, Angle spoke to Medtech Insight to probe deeper about its presentation at the 2021 Jefferies Healthcare Conference.
Minute Insight: iSTAR Medical Receives CE Mark For Glaucoma Device
MINIject has been approved in Europe for open-angle glaucoma patients.
Point Of Care Diagnostics In 2022: New Technology But Old Problems
Following a busy year for point of care diagnostics, the industry is facing a period of consolidation. The drive for new technologies is being countered by regulatory and financial issues.
Minute Insight: Olympus Corporation Joins VC Race With Its Own Fund
The Japanese company is hoping to access breaking technologies sooner via earlier investment.
Congenica Tries To Bring Clarity To Personalized Medicine For Rare Diseases
Medtech Insight spoke to David Atkins, the CEO of genomics company Congenica, to learn more about how its platform is being used in one of the largest genetics studies to date. The company expects the technology to eventually transform treatment of rare diseases.